Post Thumb

Is this the anti-aging pill we've all been waiting for?

Share it

The company had sought to see whether giving low doses of a drug called everolimus to people over 65 increased their response to flu vaccines. Behind the test was a bigger question about whether any drug can slow or reverse the symptoms of old age.

Last week a Boston company, PureTech Health, said it was licensing two drug molecules, and the right to use them against aging-related disease, from Novartis and making the research the basis of a startup company, resTORbio.

The company says it will further test whether such drugs can rejuvenate aged immune cells. The drug Novartis tested is a derivative of rapamycin, a compound first discovered oozing from a bacterium native to Easter Island, or Rapa Nui, and named after it.

Brian Kennedy, who researches aging at the Buck Institute, says the Novartis study was “Groundbreaking” because of how it found a way to address the drug’s impact on the effects of age.

The startup will try to use the Novartis drugs to reverse what it calls “Immunosenescence,” or detrimental changes to the immune system that occur with age.


Article originally posted at

Post Author: Carla Parsons

1 thought on “Is this the anti-aging pill we've all been waiting for?

    Sushant Khanal

    (October 29, 2017 - 7:49 am)

    no this is not it, and more promising pills will come and will continue to disappoint us but we’ll keep trying and succeed, but that succeess is still many failures away

Leave a Reply

Your email address will not be published. Required fields are marked *